Felbel D, Paukovitsch M, Förg R, Stephan T, Mayer B, Keßler M, Tadic M, Dahme T, Rottbauer W, Markovic S, Schneider L
Department of Cardiology, Angiology, Pneumology and Intensive Care, University Hospital Ulm, Ulm, Germany.
Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany.
Front Cardiovasc Med. 2023 Jan 25;9:1063070. doi: 10.3389/fcvm.2022.1063070. eCollection 2022.
Evidence regarding favorable treatment of patients with functional mitral regurgitation (FMR) using transcatheter edge-to-edge repair (TEER) is constantly growing. However, there is only few data directly comparing TEER and surgical mitral valve repair (SMVr).
To compare baseline characteristics, short-term and 1-year outcomes in FMR patients undergoing mitral valve (MV) TEER or SMVr using a meta-analytic approach.
Systematic database search identified 1,703 studies reporting on TEER or SMVr for treatment of FMR between January 2010 and December 2020. A meta-analytic approach was used to compare outcomes from single-arm and randomized studies based on measures by means of their corresponding 95% confidence intervals (CI). Statistical significance was assumed if CIs did not overlap. A total of 21 TEER and 37 SMVr studies comprising 4,304 and 3,983 patients were included.
Patients in the TEER cohort presented with higher age (72.0 ± 1.7 vs. 64.7 ± 4.7 years, < 0.001), greater burden of comorbidities like hypertension ( < 0.001), atrial fibrillation ( < 0.001), lung disease ( < 0.001) and chronic renal disease ( = 0.005) as well as poorer left ventricular ejection fraction (30.9 ± 5.7 vs. 36.6 ± 5.3%, < 0.001). In-hospital mortality was significantly lower with TEER [3% (95%-CI 0.02-0.03) vs. 5% (95%-CI 0.04-0.07)] and 1-year mortality did not differ significantly [18% (95%-CI 0.15-0.21) vs. 11% (0.07-0.18)]. NYHA [1.06 (95%-CI 0.87-1.26) vs. 1.15 (0.74-1.56)] and MR reduction [1.74 (95%-CI 1.52-1.97) vs. 2.08 (1.57-2.59)] were comparable between both cohorts.
Despite considerably higher age and comorbidity burden, in-hospital mortality was significantly lower in FMR patients treated with TEER, whereas a tendency toward increased 1-year mortality was observed in this high-risk population. In terms of functional status and MR grade reduction, comparable 1-year results were achieved.
关于经导管缘对缘修复术(TEER)治疗功能性二尖瓣反流(FMR)患者的有利证据不断增加。然而,直接比较TEER和外科二尖瓣修复术(SMVr)的数据很少。
采用荟萃分析方法比较接受二尖瓣(MV)TEER或SMVr的FMR患者的基线特征、短期和1年结局。
系统数据库检索确定了1703项关于2010年1月至2020年12月期间TEER或SMVr治疗FMR的研究。采用荟萃分析方法,根据单臂研究和随机研究的测量结果及其相应的95%置信区间(CI)比较结果。如果CI不重叠,则认为具有统计学意义。总共纳入了21项TEER研究和37项SMVr研究,分别包含4304例和3983例患者。
TEER队列中的患者年龄较大(72.0±1.7岁对64.7±4.7岁,P<0.001),合并症负担更重,如高血压(P<0.001)、心房颤动(P<0.001)、肺部疾病(P<0.001)和慢性肾病(P=0.005),左心室射血分数也更低(30.9±5.7%对36.6±5.3%,P<0.001)。TEER组的住院死亡率显著更低[3%(95%-CI 0.02-0.03)对5%(95%-CI 0.04-0.07)],1年死亡率无显著差异[18%(95%-CI 0.15-0.21)对11%(0.07-0.18)]。两组的纽约心脏协会(NYHA)功能分级[1.06(95%-CI 0.87-1.26)对1.15(0.74-1.56)]和二尖瓣反流(MR)减轻程度[1.74(95%-CI 1.52-1.97)对2.08(1.57-2.59)]相当。
尽管TEER治疗的FMR患者年龄和合并症负担明显更高,但其住院死亡率显著更低,而在这一高危人群中观察到1年死亡率有增加趋势。在功能状态和MR分级降低方面,两组1年结果相当。